Cannabinoid receptor-1 (CB1R) agonists have been shown to directly downregulate activity of cultured RBL-2H3 mast cells and mast cell activity in oxazolone-dermatitis [18] and topical THC has been shown to reduce symptoms of DNFB-dermatitis independent of CB1 and CB2 receptors [16]. This evidence concerns the gene CNR1 and skin disorder.